AASLD

Day 2 is bringing the energy! Make sure you head over to the President’s Welcome and Exhibit Hall Opening Reception this evening. 🎟️ Ticketed event ⭐ AASLD members or invite only

Day 1 of #TLM26 is in the books! We love seeing all your familiar faces, welcoming new ones, and watching the liver community come together for another year of learning and networking. We’re just getting started! Who’s ready for Day 2? 🙋

Resmetirom or semaglutide? Tomorrow, two teams of fellows face off at the #TLM26 Academic Debate. 🥊 Add it to your agenda in the #TLM26 app. 📲

The #TLM26 Poster Hall is where research meets conversation. Attendees have the opportunity to explore the latest findings, connect directly with poster authors, and dive deeper into the research shaping liver care. Today’s presentations spanned topics from MASLD, molecular biology, autoimmune liver diseases, and more. Don’t forget to also stop by the Poster Hall tomorrow, Saturday, and Sunday during presentation hours from 1-2pm to ask questions, exchange ideas, and connect with the researchers behind the work!

Turn your floor exploration into prizes and let the Liver Quest begin! 🔍 Every day from Thursday through Sunday at #TLM26, follow the clues, find the three Liver Quest QR codes, and scan them in the #TLM26 mobile app by 7 PM MT for a chance to win that day’s prize. 🏆 Keep playing all week: the person with the most points will be entered to win an all-access #TLM27 pass! 📲 Clues arrive in your inbox via the Daily News and in app notifications. Winners are announced in the next day’s Daily News. bit.ly/4AyIIin

🚨 BREAKING RESEARCH NEWS: Phase III Clinical Trial Results Published in @HEP_Journal AASLD is proud to announce the publication of positive Phase III results from the ELSPIRE trial in HEPATOLOGY, AASLD’s flagship journal. The study evaluated elafibranor, a PPAR-α/δ agonist, as a second-line treatment for patients with Primary Biliary Cholangitis (PBC) who continue to experience elevated alkaline phosphatase ALP levels despite treatment with, or intolerance to, ursodeoxycholic acid. These findings represent an important advancement in PBC research and underscore the continued pursuit of new therapeutic options for patients with unmet treatment needs. 🔗 Read the full study: bit.ly/4zvNFbx

#TLM26 if officially underway! 🙌 It’s great to see the hepatology community back together to learn, connect, and advance liver disease research and care. Let’s get this meeting started!

🚨 #TLM26 Late-Breaking Abstracts are now live! 🔬 From advances in #hepatitisB and #MASLD/#MASH to emerging RNA editing therapies, late-stage clinical trials, and new diagnostic approaches, these studies highlight the latest developments in #liverresearch. Explore the research shaping the future of #hepatology! 🔗 bit.ly/4sKwaBI

Day 1 of #TLM26 is finally here and there’s so much to look forward to! Check out today’s schedule and start planning your day.

We can't wait to see our hepatology community tomorrow! 🤗 Before you dive into your #TLM26 conference experience, swipe through for key information to help you navigate your week.

Here's your #TLM26 week-at-a-glance! Take a look at what's happening throughout the week and start planning your experience. 📌 Visit the TLM website or mobile app for the full schedule, event details, and updates.

Your voice can help shape national consensus on #liverfibrosis screening! At #TLM26, join AASLD for an interactive session building on our national initiative to advance early detection of #liverdisease. Hear the proposed consensus statements, share your perspectives, and help ensure recommendations are practical for real-world clinical care. 📅 Sunday, Nov. 8 | 8–9:30 a.m. MST 📍 Bluebird Ballroom 2ABC 🔗 bit.ly/4e4gsuZ

The Liver Meeting is next week!🎉 Are you attending in Denver? We created four social media graphics to help you share your excitement and let your network know you’ll be at #TLM26. Download, share, and don’t forget to tag AASLD and use #TLM26 to help us ELEVATE the liver community!

Now online in @HEP_Journal! 🌎 A unified global approach to acute-on-chronic liver failure #ACLF. The new consensus developed by #AASLD, @EASLnews, @APASLnews, @alehlatam, and @Solda_Society establishes a shared framework for diagnosing and managing ACLF, guiding #livertransplantation, and advancing clinical research. This international collaboration aims to improve consistency in care and accelerate progress toward better patient outcomes worldwide. 📗 View the consensus: bit.ly/4BulOK1 Attending #TLM26? Explore the findings during the Results of Multi-Society ACLF Harmonization session on Nov. 7: bit.ly/4ifUYOh @JasmohanBajaj @DebbieShawcros1 @ProfPaoloAngeli @mark_sonderup

Palliative care starts with your patients. Access "Palliative Care and Advanced Liver Disease" to help you understand their needs and provide treatment options for debilitating physical and psychological symptoms of decompensated #cirrhosis. Access now: bit.ly/4wSLJHS #palliativecare #hospice #livercancer

Put every session, map, and live schedule update right in your pocket by downloading the official #TLM26 mobile app! Whether you're building your agenda, locating exhibit booths, or adjusting your plan between sessions, the app keeps your entire conference experience seamlessly organized in one place. 📲 Enable push notifications to receive instant alerts on live updates and announcements throughout the meeting. You will need your TLM registration number at login to access. #AASLD #Hepatology

📣New Program available on your on-the-go platform, LiverLearning®. Get started on AASLD's newly released "Liver Cancer Systemic Therapy Certificate Program," designed to teach learners how to navigate complex treatment that balance both the tumor and liver, strategies for high-functioning tumor boards, and support that optimize patient care. Start now: bit.ly/4iaCIFZ #hcc #LiverCancerAwarenessMonth #systecmictherapy